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Abstract
Background: In FEVAR, visceral stents provide continuity and maintain perfusion between the main body of the stent
and the respective visceral artery. The aim of this study was to characterise the incidence and mode of visceral stent
failure (type Ic endoleak, type IIIa endoleak, stenosis/kink, fracture, crush and occlusion) after FEVAR in a large cohort of
patients at a high-volume centre.
Methods: A retrospective review of visceral stents placed during FEVAR over 15 years (February 2003-December
2018) was performed. Kaplan-Meier analyses of freedom from visceral stent-related complications were performed. The
outcomes between graft configurations of varying complexity were compared, as were the outcomes of different stent
types and different visceral vessels.
Results: Visceral stent complications occurred in 47/236 patients (19.9%) and 54/653 stents (8.3%). Median follow up
was 3.7 years (IQR 1.7–5.3 years). There was no difference in visceral stent complication rate between renal, SMA and
coeliac arteries. Visceral stent complications were more frequent in more complex grafts compared to less complex
grafts. Visceral stent complications were more frequent in uncovered stents compared to covered stents. Visceral stent-
related endoleaks (type Ic and type IIIa) occurred exclusively around renal artery stents. The most common modes of
failure with SMA stents were kinking and fracture, whereas with coeliac artery stents it was external crush.
Conclusion: Visceral stent complications after FEVAR are common and merit continued and close long-term surveil-
lance. The mode of visceral stent failure varies across the vessels in which the stents are located.
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Introduction
Fenestrated endovascular aneurysm repair (FEVAR) is
an adaptation of EVAR in which the proximal seal is
extended above the level of the renal arteries into the
visceral segment of the aorta. Fenestrations in the main
body of the graft permit adjunctive stenting into the
visceral vessels enabling continued perfusion of the
abdominal viscera while maintaining exclusion of
the abdominal aortic aneurysm (AAA). It was first
described in 19991 and since then has become an estab-
lished method of repair for juxtarenal AAAs and
aneurysms that involve the visceral segment of the
aorta.
It has been demonstrated that FEVAR is a feasible
treatment modality across multiple centres in large reg-
istries2,3 as well as in several cases reporting mid-term
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follow-up.4,5 However, the concern of endovascular
aneurysm repair has always been long-term durability
and FEVAR is no exception. The Globalstar registry, a
prospective multicentre database highlights reinterven-
tion rates of 7% at 30 days and 30% at 3 years after
FEVAR.2
Over time, the configuration of a standard FEVAR
device has increased in complexity from initial experi-
ence being limited to fenestrations just for the renal
arteries. Modern day practice routinely involves stent-
ing all four visceral vessels (right renal artery, left renal
artery, superior mesenteric artery and coeliac artery)
through fenestrations.6 This progression towards a
higher seal in the visceral aorta has been with the inten-
tion of reducing the risk of proximal endoleak and there-
fore increasing durability by sealing in healthier aorta.
However, this introduces more components and junc-
tions to the device, thereby increasing the risk of devel-
oping other stent graft-related complications,
particularly with respect to the visceral stents. These
may include occlusion, fracture, kink and high pressure
endoleaks from the interface between the visceral stent
and the native visceral artery (Ic endoleak) or between
the visceral stent and the fenestration (IIIa endoleak).
The aim of this study was to retrospectively charac-
terise the incidence and mode of visceral stent failure
after FEVAR and to identify predisposing factors in a
large cohort of cases performed in a high-volume centre.
Methods
This study involved extending data collection from that
of a previous study undertaken at our institution.6
Clinical details regarding the implantation of FEVAR
devices and follow-up protocols of our institution have
been described earlier.6 However, in brief, patients were
enrolled onto a standardised post-FEVAR surveillance
protocol, including plain abdominal X-ray before
discharge, duplex ultrasonography and single arterial-
phase CT angiography (CTA) after 1month, with clin-
ical review 6weeks after surgery. Abdominal X-ray,
duplex ultrasonography and CTA were repeated after
6months, then annually. All patients were placed onto
lifelong single antiplatelet and statin therapy if they
were not already prescribed it pre-operatively.
Data collection
A prospectively maintained clinical database was inter-
rogated to identify FEVARs that were undertaken at
the Liverpool Vascular and Endovascular Service
between February 2003 and December 2018. Patients
who underwent an endovascular aneurysm repair with
a branched device, a hybrid branched and fenestrated
device or a FEVAR coupled with a proximal thoracic
extension were excluded to avoid confounding of the
anatomical cohort with thoracoabdominal aneurysms.
Retrospective data collection from electronic
records (both clinical notes and imaging reports) was
undertaken to retrieve details regarding patient demo-
graphics, FEVAR configuration, stent type (if present)
and details of complications and reinterventions. A fen-
estration was defined as a deliberate defect either cir-
cular or elliptical below the proximal fabric margin and
a scallop as a U-shaped gap in the proximal fabric of
the graft.7 Low complexity FEVAR was defined as
those cases in which the most proximal visceral stents
were in the renal arteries and high complexity FEVAR
was defined as those cases in which the most proximal
stents were placed in either the superior mesenteric
artery or coeliac artery.
Study endpoints and follow up
The primary endpoint was development of any visceral
stent-related complication. Secondary endpoints were
re-intervention for any visceral stent-related complica-
tion and survival. The incidence of specific stent-related
complications (occlusion, fracture, kink, visceral type
Ic and type III endoleaks) was also recorded. Visceral
type Ic endoleaks were defined as originating from a
loss of seal between the distal visceral stent and the
target visceral vessel. Type IIIa endoleaks were defined
as originating from a loss of seal between the proximal
visceral stent and its associated fenestration.
Patients were censored at the point of last data col-
lection (1st June 2019) or the date of last follow-up if
earlier. The date of last follow-up for patients was
defined as the date of last surveillance scan (if patient
was known to be alive and on surveillance) or the date
of death.
Statistical analysis
Continuous data are presented as median (IQR).
Simple descriptive statistics were used to describe
patient demographics and incidence of various visceral
stent related complications. Visceral stent complication
rate and rate of re-intervention for visceral stent com-
plication were subject to Kaplan-Meier analysis and




During the 15-year study interval, 236 patients under-
went an elective fenestrated endovascular aneurysm
repair and met the inclusion criteria for this analysis.
215 out of 236 patients (91%) were male and the
2 JRSM Cardiovascular Disease
median age at the time of aneurysm repair was 75 (IQR
70–79). 11 patients died as an inpatient (in-hospital
mortality of 4.7%). 30-day mortality was 2.5%.
Median follow-up was 3.7 years (IQR 1.7 years – 5.3
years).
FEVAR stent graft configurations and visceral
stent details
653 visceral stents were incorporated into the fenestrat-
ed endovascular repairs of 236 patients. There were 664
fenestrations in total (11 fenestrations were unstented).
The median number of fenestrations was 3 (IQR 2–4).
The median number of visceral stents per graft was 3
(IQR 2–3). The commonest most proximal stent across
all FEVAR configurations was the SMA (97/236,
41%), followed by renal artery (84/236, 36%), followed
by coeliac artery (55/236, 23%). The most common
FEVAR configuration (Table 1) involved stenting up
to and including the SMA, with a scallop for the coe-
liac artery, placed in 77 out of 236 patients (33%).
This was followed by stents in the renal arteries
with a scallop for the SMA, placed in 68 out of 236
patients (29%).
SMA, superior mesenteric artery; CA, coeliac artery
233/236 patients underwent repair with the Zenith
Fenestrated platform (ZFEN, Cook Medical
Bloomington, IN, USA) and 3/236 patients underwent
repair with the Vascutek-Terumo Anaconda device
(Inchinnan, Scotland, UK).
Of the 653 visceral stents (all balloon expandable), it
was not possible to extract data regarding brand or
covered/uncovered status for 25. Of the remainder, 68
(10.8%) were bare metal uncovered stents and 560
(89.2%) were PTFE covered stents (Table 2). The
most common stents used in the study population
were the Advanta covered stent (Atrium Medical,
Hudson, NH, USA) and the Palmaz Genesis bare
metal uncovered stent (Cordis, Miami Lakes, Florida,
USA). Both covered and uncovered stents were used
between 2003 and 2010 for the visceral vessels, with
exclusive use of covered stents occurring between
2010 and 2018.
Overall visceral stent complications
Visceral stent complications (fracture, stenosis/kink,
crush, occlusion, dislocation, type Ic endoleak and
type IIIa endoleak) occurred in 47 out of 236 patients
(20%) and 54 out of 653 stents (8.3%) during the 15-
year study period (7 patients had more than 1 visceral
stent affected by complications). Of the 54 stents affect-
ed, 19 stents were in the right renal artery, 18 in the left
renal artery, 13 in the SMA and 4 in the coeliac artery
(Table 3).
Loss of visceral stent patency (crush or occlusion)
(Table 3)
18 stents in 18 different patients suffered from either
occlusion or crush from an extrinsic crushing force.
Primary visceral stent patency was therefore 97.2%
by stent (635/653 stents patent) or 92.3% by patient
(218/236 patients free from stent occlusion). 13 stents
occluded (12 renal arteries and 1 SMA) and in addition
to this, stent crushes (extrinsic) occurred in 5 cases (1
renal artery, 1 SMA and 3 coeliac arteries). In these
cases, there was either no flow or disturbed flow seen
through these stents on imaging. These were categor-
ised as crushes as opposed to occlusions due to the
extrinsic mechanism of action.
Of the 13 stent occlusions, 9 seemed to occur de
novo and 4 occurred after or in association with stent
fracture. 2 of the stent occlusions (both renal stents)
were peri-operative complications, 2 additional renal
Table 1. FEVAR configurations utilised in study population.
Most proximal stent SMA involvement CA involvement n %
Renal Nil Nil 14 36
Unstented fenestration Unstented fenestration 1
Unstented fenestration Nil 1
Scallop Nil 68
SMA Stent Nil 10 41
Stent Unstented fenestration 10
Stent Scallop 77
Coeliac Stent Stent 55 23
Table 2. Stents used in study population.
Stent type Stent name Manufacturer n %
Uncovered Palmaz Genesis Cordis 53 10.8
AVE Bridge Medtronic 14
Racer Medtronic 1




Unclassified n/a n/a 25 n/a
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stents occluded within the first year after FEVAR, with
the remainder occurring after 1 year. Median time to
stent occlusion was 1 year 8months (range 0 days – 4
years 9months). Stent crush was iatrogenic at open
laparotomy in the case of 1 renal stent at 10 years
9months, idiopathic in 1 SMA stent at 1 year
11months, and secondary to median arcuate ligament
compression in 3 coeliac artery stents (at 1month,
1.4months and 1 year 1month after surgery
respectively).
Fractures, kinks, dislocations and endoleaks
(Table 3)
There were 14 stent fractures in total, 8 in renal stents
and 6 in SMA stents. 4 of the renal stent fractures led
to visceral stent occlusion. 10 stents displayed velocity
changes on duplex ultrasonography that led to a diag-
nosis of kinking/stenosis. 5 out of 10 kinked/distorted
stents were in the SMA.
Type Ic and IIIa endoleaks occurred exclusively in
association with renal artery stents, with no endoleaks
identified around SMA or coeliac artery stents.
Dislocations at the level of the fenestration led to
type IIIa endoleaks in 6 left renal stents and 5 right
renal stents. There were 3 additional dislocations that
did not cause an identifiable endoleak on imaging.
Dislocations at the level of the visceral target vessel
led to a loss of seal and type Ic endoleak in 5 left
renal stents and 1 right renal stent.
Predictors of visceral vessel complications
There was no difference in the incidence of visceral
stent complications between renal stents, SMA stents
and coeliac artery stents (freedom from complications
89%, 86% and 90% respectively at 10 years, p¼ 0.25,
Figure 1). The incidence of visceral stent complications
was higher in uncovered stents compared to covered
stents (freedom from complications 64.5% vs 92%
respectively at 10 years, p¼ 0.0003, Figure 2 and
Table 4). There was a significant difference in
complication rate between stents of different brand
(p< 0.0001, Figure 3). Of covered stents, LifeStream
stents (Bard Peripheral Vascular, Tempe, AZ, USA)
appear to have a high rate of developing stent related
complications (Figure 3 and Table 4). There were more
visceral stent complications in high complexity
FEVARs, where there are stents in the SMA and/or
coeliac artery, as compared to low complexity
FEVARs, where there are stents in the renal arteries
alone (freedom from complications 66% vs 85%
respectively at 10 years, p¼ 0.02, Figure 4). Renal
stents were not more likely to suffer from a stent com-
plication if they were part of a high complexity
FEVAR configuration compared to a low complexity
FEVAR configuration (freedom from complications
86% vs 92% respectively at 10 years, p¼ 0.84,
Figure 5).




(without EL) Fracture Kink/stenosis Occlusion TIb EL TIIIa EL
Left Renal 18 1 2 3 1 5 5 6
Right Renal 19 0 1 5 3 7 1 5
SMA 13 1 0 6 5 1 0 0
CA 4 3 0 0 1 0 0 0
SMA,superior mesenteric artery; CA, coeliac artery; EL, Endoleak; TIb, Type 1b; TIIIa, Type 3a
Figure 1. Kaplan Meier curves demonstrating freedom from
visceral stent complications between coeliac, renal and SMA
stents.
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Re-intervention for visceral stent complications
Of the 47 patients who developed a visceral stent com-
plication, 26 underwent a re-intervention and 21 were
managed conservatively. Rate of re-intervention specif-
ically for visceral stent complications is therefore 11%
(26/236 patients). 25/26 patients underwent 1 or more
endovascular re-interventions (96.2%) to their visceral
stent, which was either re-lining, stent extension or
angioplasty (including re-locking at the fenestration).
Only 1 patient required an open re-intervention (an
ilio-SMA bypass for a bare metal SMA stent fracture
within 3months of the original FEVAR). There were
significantly more re-interventions to the visceral stents
of high complexity FEVARs compared to those in low
complexity FEVARs (freedom from re-intervention
70% vs 90% at 10 years, p¼ 0.0015, Figure 6).
Discussion
The 15-year study period in this retrospective review is
longer than in any published study in the current
Table 4. Incidence of visceral stent complications by brand of stent.




that brand of stent (%)
Uncovered Palmaz Genesis Cordis 53 13 24.5
AVE Bridge Medtronic 14 1 7.1
Racer Medtronic 1 1 100
Covered Advanta Atrium 502 31 6.1
BeGraft Bentley 31 1 3.2
LifeStream Bard 15 5 33.3
Jostent Jomed 12 1 8.3
Unclassified n/a n/a 25 1 –
Figure 2. Kaplan Meier curves demonstrating freedom from
visceral stent complications between covered and uncovered
stents.
Figure 3. Kaplan Meier curves comparing incidence of visceral
stent complications between different brands of stent.
Figure 4. Kaplan Meier curves comparing incidence of visceral
stent complications between low complexity and high complexity
FEVARs.
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literature to our knowledge. The study population is
comparable to other large cohorts in terms of basic
patient demographics and survival rates.2,4 Loss of
patients to follow-up as a result of out-of-region sur-
veillance as well as natural attrition from death explain
the median follow-up of 3.7 years. Specific visceral stent
complications, other than loss of patency, are rarely
reported in case series reporting FEVAR outcomes
due to a focus on mortality and overall complication
or reintervention rates in early experiences of FEVAR.
Our centre has established experience with FEVAR,
and this provided an opportunity to characterise more
specific complications affecting visceral stents.
Our results demonstrate that visceral stent compli-
cations are common, affecting 20% of patients
undergoing FEVAR. Half of these complications war-
ranted re-intervention (11% of the overall study popu-
lation). Given that stent-related complications and
their reinterventions after standard EVAR are of sim-
ilar incidence and are considered the technology’s
Achilles’ heel,8 then visceral stent complications after
FEVAR should also be considered significant sequelae.
Visceral stent complications can lead to death, either
through visceral organ malperfusion or aneurysm rup-
ture after high-pressure endoleak. Neither scenario was
seen in this study population suggesting that the deci-
sion making for reintervention was entirely appropriate
and that certain visceral stent complications may have
a benign natural history.
Stent patency in our cohort was >90% of all stents
or patients during follow-up which is comparable to
the published rate in the literature.2,9,10 Interestingly,
stent occlusion was seen to occur either de novo, after
stent fracture or due to extrinsic compression of the
coeliac artery by the median arcuate ligament (MAL).
Visceral type Ic and IIIa endoleaks were only seen in
association with renal artery stents. This has also been
described in a cohort of 18 hybrid fenestrated/branched
EVAR cases (F/BEVAR), all treated with the
LifeStream visceral stent specifically.11 In that cohort,
type IIIa endoleaks occurred at 22% of all fenestrations,
the majority (5 out of 7 type IIIa endoleaks) occurring at
the renal artery fenestrations. This high rate of type IIIa
endoleak development was attributed to the mechanical
properties of the LifeStream stent. In our case series,
33% of 15 LifeStream stents suffered from stent com-
plications, a greater proportion than any of the other
PTFE covered stents, although low numbers precluded
statistical analysis. Our analysis demonstrated that
PTFE covered stents suffered from fewer complications
than bare metal uncovered stents. This finding is not
novel12 and covered stents are now standard practice
for FEVAR deployment across the world. It is however
useful to note that in long-term follow-up, covered
stents continue to outperform the bare metal stents
that were used only in the early days of FEVAR prac-
tice. It is also useful to recognise this as patients will
continue to present to FEVAR centres with complica-
tions to uncovered visceral stents in the long-term.
Our analysis has demonstrated quite clearly that the
mode of stent graft failure varies between the different
visceral arteries. Coeliac stents are prone to crush from
the median arcuate ligament, whereas SMA stents are
prone to fracture and kinking. An explanation might
be the possibility of there being a relatively high level of
movement in this segment of the FEVAR graft. The
caudal direction of the SMA also necessitates an angu-
lated passage of the stent through the fenestration
which may apply additional forces greater than those
acting on stents located in the renal arteries. Renal
Figure 5. Kaplan Meier curves comparing incidence of renal
stent complications between low complexity and high complexity
FEVARs.
Figure 6. Kaplan Meier curves comparing re-intervention rates
for visceral stent complications between low complexity and
high complexity FEVARs.
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stents were the only visceral vessels affected by type Ic
and type IIIa endoleaks, perhaps related to smaller
diameter stents being placed in larger fenestration
sizes (6 6mm and 6 8mm) and the short engage-
ment lengths often utilised within the renal artery due
to early branches. Additionally, graft tapering of the
fenestrated piece often commences at the level of the
renal arteries, potentially reducing wall apposition at
this level. These hypotheses cannot be investigated fully
in the absence of anatomical data from pre-operative
CT scans and their relationship to sizing of the FEVAR
graft.
The observations made in this analysis may help
inform decision making at the planning and intra-
operative stages of FEVAR. Covered renal stents
could possibly be lined with a bare metal stent across
the fenestration in an attempt to improve sealing and
avoid type IIIa endoleak. SMA stents could be similar-
ly reinforced in an attempt to improve stability during
the phases of the cardiac cycle in which the stent will be
maximally flexed. Coeliac arteries could either be left
unstented in cases where there is pre-operative radio-
logical evidence of MAL compression or alternatively
reinforced with a second stent intra-operatively or with
the use of high pressure ballooning. These suggestions
are hypothetical and would merit further investigation.
Over time, FEVAR has become more complicated
with regards to the proximal extent of seal zone and
the number of visceral vessels involved.6 This has
occurred with the intention of increasing long-term
durability, as sealing in more proximal ‘healthier”
aorta will increase the likelihood of achieving a suc-
cessful seal. However, the trade-off is an increase in
the amount of stent graft material, the number of
components and the number of junctions at which
novel complications can develop.
Increasing complexity of FEVAR configuration is
associated with an increased incidence of visceral
stent graft-related complications. Two hypotheses
could explain this: firstly, that the more complex
FEVARs have more junctions and components and
will therefore experience more complications by
default. However, it is also possible that high complex-
ity FEVAR is a surrogate marker for more complex
anatomy and an unhealthier visceral segment of the
aorta. It is known that type IIIa endoleaks in particular
are more common when the fenestrated piece is less
apposed to the native aortic wall, i.e. in cases of ectatic
or aneurysmal aorta.11 Therefore, it is plausible that
visceral stent complications are more common in
cases of more severe visceral segment disease. This
could independently influence the incidence of visceral
stent complications. However, we have shown that
renal stents are no more likely to experience complica-
tions in high complexity FEVAR (configurations
involving SMA/CA stents) compared to low complex-
ity FEVAR (configurations involving renal stents
only). This suggests that the discrepancy could poten-
tially be explained solely by the fact that there are more
stents to potentially fail in the complex cases.
We adopt an aggressive clinical strategy at our insti-
tution for salvaging failing visceral stents. Kinks, dis-
locations, endoleaks and fractures are all treated on an
urgent basis once identified on surveillance imaging or
on-table if identified on completion imaging. With
respect to occlusions of the SMA or CA, revascularisa-
tion was only performed in 1 case due to symptoms of
acute mesenteric ischaemia. Renal stent occlusions
were never treated. We did not report any deaths due
to visceral stent complications in our series. Data has
not been interrogated for changes in renal function
after complications to renal artery stents, although
this may be the subject of future work.
The strengths to this analysis include the fact that it
analysed a large cohort of patients over a long time
period in a high-volume vascular centre. Data were
extracted from prospectively maintained clinical
records that were electronically interrogated with
little missing data. Limitations to this study include
the retrospective nature to data collection, the loss of
patients to follow-up resulting in a median follow-up of
only 3.7 years, and the small numbers recorded for
each type of visceral stent complication (with the sub-
sequent potential for type II error) as well as the lack of
data on anatomical factors which could act as con-
founders. Furthermore, our experience over nearly 20
years of FEVAR practice would have be subject to an
initial learning curve and the impact of multiple
operators.
Conclusion
Visceral stent complications are common after
FEVAR, occurring in 20% of patients. They are asso-
ciated with bare metal stents more than covered stents
and they occur more frequently in high complexity
FEVAR configurations compared to low complexity
configurations. This could be explained by the fact
that more complex FEVAR configurations involve a
greater number of components, stents and junctions
that could fail. The mode of visceral stent failure
varies across different visceral vessels. Future work
should explore the potential anatomical influences on
these findings and the possible intraoperative strategies
that could be exploited to mitigate these risks.
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